Abstract: Wild and feral birds are known to be involved in the maintenance and dissemination of clinically-important antimicrobial-resistant pathogens, such as extended-spectrum β-lactamase (ESBL) and carbapenemase-producing Enterobacteriaceae. The aim of our study was to evaluate the presence of ESBL- and carbapenemase-producing Escherichia coli among wild and feral birds from Greece and to describe their antimicrobial resistance characteristics. In this context, fecal samples of 362 birds were collected and cultured. Subsequently, the antimicrobial resistance phenotype- and geno-type of all the obtained E. coli isolates were determined. A total of 12 multidrug-resistant (MDR), ESBL-producing E. coli were recovered from eight different wild bird species. Eleven of these isolates carried a blaCTX-M-1 group gene alone or in combination with blaTEM and one carried only blaTEM. AmpC, fluoroquinolone, trimethoprim/sulfamethoxazole, aminoglycoside and macrolide resistance genes were also detected. Additionally, one carbapenemase-producing E. coli was identified, harboring blaNDM along with a combination of additional resistance genes. This report describes the occurrence of ESBL- and carbapenemase-producing E. coli among wild avian species in Greece, emphasizing the importance of incorporating wild birds in the assessment of AMR circulation in non-clinical settings.

Keywords: ESBL; carbapenemases; blaCTX-M; blaTEM; blaNDM; Escherichia coli; multidrug-resistance; antimicrobial resistance genes; wild birds; Greece
of β-lactamases, a family of enzymes capable of hydrolyzing the amide bond of the β-lactam ring and, therefore, of rendering β-lactam antimicrobials ineffective [2]. The global establishment and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-PE) and of carbapenemase-producing Enterobacteriaceae (CPE) can be described as one of the most devastating pandemics of multidrug-resistant (MDR) organisms to date. Historically, MDR bacteria have affected patients in hospital settings, where factors such as exposure to antibiotics, artificial ventilation or catheterization provide an enhanced risk for acquisition [3,4]. However, over the last decades, both ESBL-PE and CPE are frequently detected in the community, as well as among domesticated and wild animals and in the environment [5,6].

The localization of ESBL- and carbapenemase-encoding genes on mobile genetic elements (MGEs) that can be efficiently disseminated between different bacteria and hosts, has rendered ESBL-PE and CPE a One Health problem. For instance, integrons associated with plasmids contribute to the spread of AMR due to their mobility, ability to capture different resistance genes and capacity to cluster resistance genes into complex operons, which can be expressed together and jointly diffused by horizontal gene transfer [7]. In addition to antibiotic resistance genes, ESBL and carbapenemase plasmids commonly also harbor non-resistance factors, including toxin–antitoxin systems that are related to the stable inheritance of the respective resistance genes, even in the absence of selective pressure [8].

During the past few years, antibiotic-resistant bacteria from wildlife have received increasing interest from the scientific community, and the potential contribution of wild fauna as an AMR contamination source has been widely acknowledged [9]. Special attention has been given to the role of wild and feral birds, due to their wide exposure to anthropogenic environments, relative abundance and long-range movements. Subsequently, wild and feral avian species are deemed as a reservoir and vehicle for AMR dissemination [10]. Indeed, several previous studies have identified clinically relevant resistance determinants, such as the ESBL gene \( \text{bla}_{\text{CTX-M-15}} \) and the carbapenemase gene \( \text{bla}_{\text{KPC}} \), among Enterobacteriaceae isolated from wild and feral birds [11–13]. Of note, some of these isolates additionally belonged to sequence types frequently detected in human and animal clinical cases, underlining their possible interspecies transmission [14].

Regarding bacterial species, β-lactamase research has been mainly focused on \( E. \text{coli} \), given its importance as a human and animal pathogen, its commensal nature and the fact that it can be easily disseminated in different ecosystems, enabling the direct comparison of resistance phenotypes in distinct hosts [9,15]. Enzymes of the CTX-M family, particularly those of group 1, are the most common ESBLs among \( E. \text{coli} \) of human, livestock and wild animal origin worldwide [10]. Concerning carbapenemases, Ambler class A variants of the KPC family have the most extensive global distribution among human isolates, followed by class B metallo-β-lactamases (MBLs), which are mostly prevalent in Asia, and class D OXA-type genes that are commonly found in Mediterranean countries [16–18]. Correspondingly, the carbapenemase genes identified among animal strains in different countries reflect the types of carbapenemases that prevail in human isolates within these regions [15].

Greece, due to its geographic location within the eastern Mediterranean on the intersection of three continents, constitutes an important habitat for both sedentary and migratory wild birds. High ESBL-PE prevalence and endemicity of CPE among humans has been reported [19–25], however, data regarding the presence of ESBL-PE and CPE among wild birds remain scarce and no study detailing their prevalence and characteristics is available to date. In this context, the objective of the present study was to determine the occurrence and the molecular traits of ESBL- and carbapenemase-producing \( E. \text{coli} \) among wild and feral birds from Greece.

2. Materials and Methods

2.1. Sample Collection

Between 2019 and 2021, a total number of 362 non-duplicated fecal samples were collected from 47 different wild and feral bird species (Table 1), originating from 23 regional
units of Greece. Samples were obtained by inserting a sterile cotton swab into recently deposited feces or directly into the cloaca of live, captured wild and feral birds. Birds were captured using Larsen-type traps, Australian-type traps or modified bird-catching nets, and immediately released after sampling, according to Greek legislation. Samples were only collected following bird species identification. The swabs were transported in Amies medium (Transwab® Amies, Corsham, UK) under refrigeration and arrived in the laboratory within 48 h of their collection.

Table 1. Number of samples per wild or feral bird species collected and tested.

| Family       | Common Name               | Scientific Name                  | Number of Samples |
|--------------|---------------------------|----------------------------------|-------------------|
| Accipitridae | Common buzzard            | *Buteo buteo*                     | 4                 |
|              | Eurasian sparrowhawk      | *Accipiter nisus*                 | 1                 |
|              | Short-toed snake eagle    | *Circaetus gallicus*              | 2                 |
|              | Steppe eagle              | *Aquila nipalensis*               | 1                 |
| Anatida      | Domestic Muscovy duck     | *Cairina moschata domestica*      | 1                 |
|              | Greater white-fronted goose | *Anser albifrons*                | 33                |
|              | Mallard                   | *Anas platyrhynchos*              | 10                |
|              | Mute swan                 | *Cygnus olor*                     | 5                 |
| Apodida      | Common swift              | *Apus apus*                       | 1                 |
| Ardeida      | Grey heron                | *Ardea cinerea*                   | 14                |
|              | Little egret              | *Egretta garzetta*                | 8                 |
| Charadriidae | European golden plover    | *Pluvialis apricaria*             | 1                 |
| Columbida    | Domestic pigeon           | *Columba livia domestica*         | 40                |
|              | Eurasian collared dove    | *Streptopelia decaocto*           | 18                |
| Corvidae     | Hooded crow               | *Corvus corone cornix*            | 5                 |
|              | Rook                      | *Corvus frugilegus*               | 4                 |
|              | Western jackdaw           | *Corvus monedula*                 | 3                 |
|              | Eurasian magpie           | *Pica pica*                       | 79                |
| Emberizidae  | Rock bunting              | *Emberiza cia*                    | 1                 |
| Falconida    | Common kestrel            | *Falco tinnunculus*               | 2                 |
| Fringillida  | Common chaffinch          | *Fringilla coelebs*               | 6                 |
|              | European goldfinch        | *Carduelis carduelis*             | 1                 |
| Hirundinidae | Barn swallow              | *Hirundo rustica*                 | 1                 |
| Larida       | Caspian gull              | *Larus cachinnans*                | 20                |
|              | European herring gull     | *Larus argentatus*                | 9                 |
|              | Yellow-legged gull        | *Larus michahellis*               | 8                 |
|              | Mediterranean gull        | *Larus melanocephalus*            | 2                 |
|              | Sandwich tern             | *Sterna sandvicensis*             | 1                 |
| Paridae      | Great tit                 | *Parus major*                     | 6                 |
| Passerida    | Eurasian tree sparrow     | *Passer montanus*                 | 9                 |
|              | House sparrow             | *Passer domesticus*               | 28                |
| Phalacrocoracidae | Great cormorant          | *Phalacrocorax carbo*             | 4                 |
| Phasianidae  | Green peafowl             | *Pavo muticus*                    | 2                 |
Table 1. Cont.

| Family               | Common Name       | Scientific Name          | Number of Samples |
|----------------------|-------------------|--------------------------|-------------------|
| Phoenicopteridae     | Greater flamingo  | Phoenicopterus roseus    | 5                 |
| Phylloscopidae       | Leaf warbler      | Phylloscopus spp.        | 3                 |
| Rallidae             | Common moorhen    | Gallinula chloropus      | 2                 |
| Recurvirostridae     | Black-winged stilt| Himantopus himantopus    | 2                 |
| Strigidae            | Eurasian Scops owl| Otus scops               | 1                 |
|                      | Little owl        | Athene noctua            | 2                 |
|                      | Long-eared owl    | Asio otus                | 3                 |
| Sturnidae            | Common starling   | Sturnus vulgaris         | 1                 |
| Sylviidae            | Common whitethroat| Sylvia communis          | 3                 |
|                      | Sardinian warbler | Sylvia melanocephala     | 1                 |
| Turdidae             | Common blackbird  | Turdus merula            | 7                 |
|                      | Redwing           | Turdus iliacus           | 1                 |
| Tytonidae            | Barn owl          | Tyto alba                | 1                 |
| **Total**            |                   |                          | **362**           |

2.2. Isolation, Identification and Antimicrobial-Resistance Phenotype of ESBL- and Carbapenemase-Producing Enterobacteriaceae

Swabs were directly streaked onto both ESBL selective media (CHROMID® ESBL, BioMérieux, Marcy l’Etoile, France) and CPE selective media (CHROMID® CARBA SMART, BioMérieux), and the plates were incubated aerobically at 37 °C for 24–48 h. Putative *E. coli* colonies of pink to burgundy coloration were sub-cultured on MacConkey agar. Identification and antimicrobial susceptibility testing of the isolates were performed using the Vitek-2 system (BioMérieux), according to the manufacturer’s instructions. The AST-GN96 card was used in order to determine the minimum inhibitory concentration (MIC) of the following antimicrobials: ampicillin, amoxicillin/clavulanic acid, ticarcillin/clavulanic acid, cefalexin, cefalotin, cefoperazone, ceftiofur, cefquinome, imipenem, gentamicin, neomycin, flumequine, enrofloxacin, marbofloxacin, tetracycline, florfenicol, polymyxin B and trimethoprim/sulfamethoxazole. Results were automatically interpreted using the Vitek-2 software (BioMérieux, system version 8.02). Isolates were considered MDR when they exhibited diminished susceptibility to at least one agent of more than three antimicrobial classes.

2.3. Phenotypic Confirmation of ESBL or Carbapenemase Production

*E. coli* isolates that presented resistance to third generation cephalosporins (cefoperazone, ceftiofur) were subjected to the double disk synergy test (DDST) for the phenotypic confirmation of ESBL production, according to EUCAST guidelines [26]. A positive result was indicated when the inhibition zones around any of the cephalosporin disks were augmented or when a “keyhole” was formed in the direction of the disk containing clavulanic acid.

Microorganisms that were resistant to imipenem were assessed for phenotypic carbapenemase production using MIC test strips containing meropenem plus phenylboronic acid and meropenem plus ethylendiaminetetraacetic acid (EDTA) (Liofilchem). Isolates that had a ratio meropenem/meropenem plus phenylboronic acid ≥8 or meropenem/meropenem plus EDTA ≥8 were considered positive for class A or class B carbapenemases, respectively.

2.4. Antimicrobial Resistance Genotyping of the ESBL- and Carbapenemase-Producing *E. coli*

Isolates that were found positive in the DDST or the phenotypic carbapenemase tests were characterized using the DNA microarray-based assay CarbaResist from InterArray (FZMB GmbH, Bad Langensalza, Germany). Primer and probe sequences have previously
been described in detail [27]. In addition, probes for the detection of the colistin resistance gene family mcr were included on the present microarray (see Supplementary File S1). The microarray layout is presented in Supplementary File S2. Protocols and procedures were conducted in accordance with the manufacturer’s instructions (https://www.interarray.com/Further-Genotyping-Kits, accessed on 10 May 2022). In brief, bacteria were grown overnight on Columbia blood agar, harvested and enzymatically lysed prior to DNA preparation. Genomic DNA from the bacteria was extracted using the Qiagen blood and tissue kit (Qiagen, Hilden, Germany), following the manufacturer’s instructions. The DNA was used in a multiplexed primer elongation, incorporating biotin-16-dUTP. Amplicons were stringently hybridized to the microarray, washed and incubated with a horseradish-peroxidase-streptavidin conjugate. Hybridizations were detected by adding a precipitating dye. An image of the microarray was taken for further analysis.

3. Results

3.1. Occurrence and Characteristics of ESBL-Producing E. coli

A total of 12 E. coli was found to be resistant to third-generation cephalosporins and had a positive ESBL-confirmation test (DDST). The isolates were retrieved from 12 of the 362 sampled wild and feral birds (3.3%) and, in particular, from four Eurasian magpies (Pica pica), two Common buzzards (Buteo buteo), one Short-toed snake eagle (Circaetus gallicus), one Eurasian sparrowhawk (Accipiter nisus), one Steppe eagle (Aquila nipalensis), one Grey heron (Ardea cinerea), one Eurasian Scops owl (Otus scops) and one Common swift (Apus apus). These birds originated from three regional units of Greece; Korinthia and Messinia that are located in the Peloponnese region of southern Greece, and Magnesia that is located in central Greece.

The 12 ESBL isolates presented resistance to ampicillin and first- to fourth-generation cephalosporins. One exhibited an intermediate phenotype to ticarcillin/clavulanic acid, while none were resistant to carbapenems. Molecular detection of ESBL genes showed that 11 isolates carried the blaCTX-M-1 group gene alone (n = 4) or in combination with blaTEM (n = 7) and one isolate carried the blaTEM alone. The AmpC gene blacr was detected in four of the isolates and the broad spectrum β-lactamase blaoxa-1 in only one.

All the isolates were further categorized as MDR. Reduced susceptibility to aminoglycosides was detected in one of the ESBL E. coli (1/12, 8.3%) which presented resistance to gentamicin, was intermediate to neomycin and harbored aphA. However, the remaining 11 strains were also found to possess aminoglycoside resistance genes and, in particular, adaA2 (n = 7), adaA4 (n = 3) and rmtA (n = 5).

Eleven of the isolates were additionally non-susceptible to fluoroquinolones (11/12, 91.7%), being either resistant or intermediate to both flumequine and enrofloxacin, while four of them were further resistant to marbofloxacin. The plasmid-mediated quinolone resistance gene qnrS was detected in all the fluoroquinolone-resistant E. coli. Trimethoprim/sulfamethoxazole (11/12, 91.7%) resistance was detected in 11 isolates, which harbored a combination of dfrA and sul variants. In particular, dfrA5 (n = 10) and sul2 (n = 11) were the most common alleles detected, followed by dfrA17 (n = 4) and sul1 (n = 4), respectively.

All 12 isolates were resistant to tetracycline (12/12, 100%), whereas 11 of them harbored the macrolide resistance gene mrx alone (n = 2) or in combination with mph (n = 9).

Finally, the intI1 gene was detected in two strains.

The antimicrobial resistance phenotypes and genotypes of the ESBL-producing E. coli isolates are summarized in Tables 2 and 3. An example of the microarray results is depicted in Figure 1.
Table 2. Characteristics of the ESBL- and the Carbapenemase-Producing E. coli.

| Wild Bird Species | Regional Unit of Origin | Phenotype | Antimicrobial Resistance Profile | Genotype |
|-------------------|-------------------------|-----------|---------------------------------|----------|
| Magpie (Pica pica)| Korinthia | ESBL | AMP, CEX, CF, CFP, CEF, CEQ, FLU *, ENR *, TET, SXT | bla<sub>CTX-M-1</sub> group | aadA4, qnrS, sul1, sul2, dfrA17, mph, mrx |
| Magpie (Pica pica)| Korinthia | ESBL | AMP, CEX, CF, CFP, CEF, CEQ, FLU *, ENR *, TET, SXT | bla<sub>CTX-M-1</sub> group | aadA4, rmtA, qnrS, sul1, sul2, dfrA5, dfrA17, mph, mrx |
| Magpie (Pica pica)| Korinthia | ESBL | AMP, CEX, CF, CFP, CEF, CEQ, FLU *, ENR *, TET, SXT | bla<sub>CTX-M-1</sub> group | aadA4, rmtA, qnrS, sul1, sul2, dfrA5, dfrA17, mph, mrx |
| Magpie (Pica pica)| Korinthia | ESBL | AMP, CEX, CF, CFP, CEF, CEQ, FLU *, ENR *, TET, SXT | bla<sub>CTX-M-1</sub> group | aadA4, rmtA, qnrS, sul1, sul2, dfrA5, dfrA17, mph, mrx |
| Common buzzard (Buteo buteo) | Messinia | ESBL | AMP, CEX, CF, CFP, CEF, CEQ, FLU, ENR, MRB, TET, SXT | bla<sub>CTX-M-1</sub> group, bla<sub>TEM</sub> | aadA2, qnrS, sul2, dfrA5, mph, mrx |
| Common buzzard (Buteo buteo) | Messinia | ESBL | AMP, CEX, CF, CFP, CEF, CEQ, FLU, ENR *, TET, SXT | bla<sub>CTX-M-1</sub> group, bla<sub>TEM</sub> | aadA2, qnrS, sul2, dfrA5, mph, mrx |
| Wild Bird Species | Regional Unit of Origin | Phenotype | Antimicrobial Resistance Profile |
|-------------------|-------------------------|-----------|---------------------------------|
| **Grey heron** *(Ardea cinerea)* | Magnesia | ESBL | **Genotype** |
| | | AMP, TCC *, CEX, CF, CFP, CEF, CEQ, GEN, NEO *, TET | *bla*<sub>CTX-M-1</sub> group, *bla*<sub>TEM</sub> | - | - | - | *aphA* | - | *sul2* | - | - | - |
| **Short-toed snake eagle** *(Circaetus gallicus)* | Messinia | ESBL | AMP, CEX, CF, CFP, CEF, CEQ, FLU, ENR, MRB, TET, SXT | *bla*<sub>CTX-M-1</sub> group, *bla*<sub>TEM</sub> | - | - | - | *aadA2* | *qnrS* | *sul2* | dfrA5 | *mer* | - |
| **Eurasian Scops owl** *(Otus scops)* | Messinia | ESBL | AMP, CEX, CF, CFP, CEF, CEQ, FLU, ENR, MRB, TET, SXT | *bla*<sub>CTX-M-1</sub> group, *bla*<sub>TEM</sub> | - | - | - | *aadA2* | *qnrS* | *sul2* | dfrA5 | *mph*, *mer* | int11 |
| **Common swift** *(Apus apus)* | Messinia | ESBL | AMP, CEX, CF, CFP, CEF, CEQ, FLU, ENR, MRB, TET, SXT | *bla*<sub>CTX-M-1</sub> group, *bla*<sub>TEM</sub> | - | - | - | *aadA2* | *qnrS* | *sul2* | dfrA5 | *mph*, *mer* | - |
| **Eurasian sparrowhawk** *(Accipiter nisus)* | Messinia | ESBL | AMP, CEX, CF, CFP, CEF, CEQ, FLU, ENR *, TET, SXT | *bla*<sub>TEM</sub> | - | - | - | *aadA2* | *qnrS* | *sul2* | dfrA5 | *mer* | - |
| **Steppe eagle** *(Aquila nipalensis)* | Messinia | ESBL | AMP, CEX, CF, CFP, CEF, CEQ, FLU *, ENR *, TET, SXT | *bla*<sub>CTX-M-1</sub> group, *bla*<sub>TEM</sub> | - | - | - | *aadA2* | *qnrS* | *sul2* | dfrA5 | *mph*, *mer* | - |
Table 2. Cont.

| Wild Bird Species | Regional Unit of Origin | Phenotype | Genotype | Antimicrobial Resistance Profile |
|-------------------|-------------------------|-----------|----------|----------------------------------|
| Caspian gull (Larus cachinnans) | Messinia CPE | AMP, AMC, TCC, CEX, CF, CFP, CEF, CEQ, IMI, GEN*, FLU, ENR, MRB, SXT | blaCTX-M-1 group, blaTEM | blaCTX-M-1, aadB, aadA1, aadA2, ant21a, qnrB, qnrS, sul1, sul2, dfrA5, dfrA12, mph, mrx, intI1 |

AMR—ampicillin; AMG—amoxicillin/clavulanic acid; TCC—ticarcillin/clavulanic acid; CEX—cefalexin; CF—cefalotin; CFP—cefoperazone; CEF—ceftiofur; CEQ—cefoquinome; IMI—imipenem; GEN—gentamicin; NEO—neomycin; FLU—flumequine; ENR—enrofloxacin; MRB—marbofloxacin; TET—tetracycline; SXT—trimethoprim/sulfamethoxazole; *intermediate resistance; PMQR—plasmid-mediated quinolone resistance genes; the isolate did not harbor genes of this category.

Table 3. Comparison between the microarray-based genotype and the phenotype obtained by VITEK-2 system.

| Detected AMR Genotype | AMR Gene Family | Expected AMR Phenotype | Antibiotics Tested | No of Isolates Harboring the Genotype by Microarray | No of Resistant Isolates by VITEK | No of Susceptible Isolates by VITEK | Concordance (%) |
|-----------------------|-----------------|------------------------|--------------------|-----------------------------------------------|-------------------------------|-------------------------------|----------------|
| blaCTX-M-1 group      | ESBL            | Resistant to 4G/3G cephalosporins, other β-lactams | AMP, AMC, TCC, CEX, CF, CFP, CEF, CEQ | 4                                       | 4                             | 0                             | 100            |
| blaCTX-M-1 group, blaTEM | ESBL            | Resistant to 4G/3G cephalosporins, other β-lactams | AMP, AMC, TCC, CEX, CF, CFP, CEF, CEQ | 8                                       | 8                             | 0                             | 100            |
| blaTEM (consensus)    | ESBL            | Resistant to 4G/3G cephalosporins, other β-lactams | AMP, AMC, TCC, CEX, CF, CFP, CEF, CEQ | 1                                       | 1                             | 0                             | 100            |
| blaNDM                | Carbapenemases  | Resistant to carbapenems, 3G/4G cephalosporins, other β-lactams | IMI, AMP, AMC, TCC, CEX, CF, CFP, CEF, CEQ | 1                                       | 1                             | 0                             | 100            |
Table 3. Cont.

| Detected AMR Genotype | AMR Gene Family | Expected AMR Phenotype | Antibiotics Tested | No of Isolates Harboring the Genotype by Microarray | No of Resistant Isolates by VITEK | No of Susceptible Isolates by VITEK | Concordance (%) |
|-----------------------|-----------------|------------------------|--------------------|---------------------------------------------------|-----------------------------------|-------------------------------------|-----------------|
| *bla*<sub>ACT</sub>   | AmpC            | Resistant to 4G/3G cephalosporins, other β-lactams | AMP, AMC, TCC, CEX, CF | 4                                                 | 4                                 | 0                                   | 100             |
| *bla*<sub>OXA-1</sub> | NSBL           | Resistant to other β-lactams | AMP, AMC, TCC, CEX, CF | 1                                                 | 1                                 | 0                                   | 100             |
| *bla*<sub>OXA-10</sub> | NSBL          | Resistant to other β-lactams | AMP, AMC, TCC, CEX, CF | 1                                                 | 1                                 | 0                                   | 100             |
| *aadA4*               | Aminoglycosides | Resistant to aminoglycosides | GEN, NEO            | 1                                                 | 0                                 | 1                                   | 0               |
| *aadA2*               | Aminoglycosides | Resistant to aminoglycosides | GEN, NEO            | 6                                                 | 0                                 | 6                                   | 0               |
| *aadA2, rmtA*         | Aminoglycosides | Resistant to aminoglycosides | GEN, NEO            | 1                                                 | 0                                 | 1                                   | 0               |
| *aadA4, rmtA*         | Aminoglycosides | Resistant to aminoglycosides | GEN, NEO            | 3                                                 | 0                                 | 3                                   | 0               |
| *aAB, aadA1, aadA2, ant2Ia* | Aminoglycosides | Resistant to aminoglycosides | GEN, NEO            | 1                                                 | 1                                 | 0                                   | 100             |
| *aphA*                | Aminoglycosides | Resistant to aminoglycosides | GEN, NEO            | 1                                                 | 1                                 | 0                                   | 100             |
| *qnrS*                | Quinolones      | Resistant to fluoroquinolones | FLU, ENR, MRB      | 11                                                | 11                                | 0                                   | 100             |
| *qnrB, qnrS*          | Quinolones      | Resistant to fluoroquinolones | FLU, ENR, MRB      | 1                                                 | 1                                 | 0                                   | 100             |
| *sul1, sul2, dfrA17*  | Sulfonamides -Trimethoprim | Resistant to sulfonamides/trimethoprim | SXT | 1                                                 | 1                                 | 0                                   | 100             |
| *sul1, sul2, dfrA5, dfrA12* | Sulfonamides -Trimethoprim | Resistant to sulfonamides/trimethoprim | SXT | 1                                                 | 1                                 | 0                                   | 100             |
| *sul1, sul2, dfrA5, dfrA17* | Sulfonamides -Trimethoprim | Resistant to sulfonamides/trimethoprim | SXT | 3                                                 | 3                                 | 0                                   | 100             |
Table 3. Cont.

| Detected AMR Genotype | AMR Gene Family   | Expected AMR Phenotype               | Antibiotics Tested | No of Isolates Harboring the Genotype by Microarray | No of Resistant Isolates by VITEK | No of Susceptible Isolates by VITEK | Concordance (%) |
|-----------------------|-------------------|--------------------------------------|--------------------|-----------------------------------------------------|-----------------------------------|-------------------------------------|-----------------|
| sul2, dfrA5           | Sulfonamides      | Resistant to sulfonamides/trimethoprim| SXT                | 7                                                   | 7                                 | 0                                   | 100             |
| sul2                  | Sulfonamides      | Susceptible to sulfonamides/trimethoprim| SXT                | 1                                                   | 0                                 | 1                                   | 100             |
| Overall concordance (mean) |                   |                                      |                    |                                                     |                                   |                                     | 80%             |

AMP—ampicillin; AMC—amoxicillin/clavulanic acid; TCC—ticarcillin/clavulanic acid; CEX—cefalexin; CF—cefalotin; CFP—cefoperazone; CEF—ceftiofur; CEQ—cefquinome; IMI—imipenem; GEN—gentamicin; NEO—neomycin; FLU—flumequine; ENR—enrofloxacin; MRB—marbofloxacin; SXT—trimethoprim/sulfamethoxazole; NSBL—narrow spectrum β-lactamases.
3.2. Occurrence and Characteristics of Carbapenemase-Producing E. coli

Among the 362 samples tested, only one, originating from a Caspian gull (Larus cachinnans), yielded a positive culture on the CPE selective media (1/362, 0.3%). The isolated E. coli strain was resistant to imipenem and was phenotypically detected to produce MBL in the meropenem-EDTA test.

This isolate was MDR, also being resistant to the other β-lactams, as well as to gentamicin, flumequine, enrofloxacin, marbofloxacin and trimethoprim/sulfamethoxazole, while it was susceptible to neomycin and tetracycline.

AMR genotyping revealed that the isolate harbored the carbapenemase gene blanDM, as well as genes encoding for other β-lactamases (blaCTX-M-1/15, blatem, blaOXA-10). Additionally, genes associated with aminoglycoside (aadB, aadA1, aadA2, ant2Ia), quinolone (qnrB, qnrS), sulfonamide (sul1, sul2), trimethoprim (dfrA5, dfrA12) and macrolide (mph, mrx) resistance were detected. The isolate also carried the intI1 gene.

The antimicrobial resistance phenotype and genotype of the carbapenemase-producing E. coli is presented in Tables 2 and 3.

4. Discussion

The present study describes the occurrence and the molecular characteristics of ESBL- and carbapenemase-producing E. coli recovered from wild and feral birds’ feces in Greece. The incidence of ESBL-producing E. coli was rather low (3.3%), which is in accordance with reports from Italy (4/103, 3.9%) [28], Sweden (3/100, 3%) [29], Brazil (5/204, 2.4%) [30] and Alaska (3/76, 3.9%) [31]. The presence of carbapenemase-producing E. coli was even lower (0.3%) and comparable to that identified in recent research from other countries, including Spain [32].

However, our results differ significantly from former studies that have reported higher ESBL detection rates in Chile (67/124, 54%) [33], Spain (68/132, 51.5%) [34], Pakistan (26/150, 17.3%) [35] and The Netherlands (51/414, 12.3%) [36], as well as comparatively elevated CPE detection rates in Tunisia (2/150, 1.3%) [12], Algeria (3/32, 9.4%) [37], France (22/158, 13.9%) [38] and Australia (120/504, 23.8%) [39]. This discrepancy could be attributed either to a lower prevalence of such resistant bacteria in the region or to the fact that many prior studies have only been focused on “target” wild bird species, i.e., migratory, omnivorous and aquatic birds. Nevertheless, the systematic review conducted by Chung et al. (2018) has highlighted that, based on the birds migratory status and habitat type, no significant differences in antibiotic resistance rates are observed [40]. Subsequently, in this study, we evaluated ESBL and CPE carriage in several species, including not only high-risk ones, for screening purposes.
ESBL-producing *E. coli* was retrieved from eight different wild bird species. Four species; Common buzzard, Short-toed snake eagle, Steppe eagle and Eurasian sparrow hawk, are raptors and two; Steppe eagle and Eurasian magpie, can be considered omnivores and scavengers. Their diet, which is commonly in direct contact with anthropogenic environments and agricultural animals and waste, constitutes a major potential route for ESBL acquisition [41]. Another alternative pathway is the environment inhabited by the aforementioned species, as also applies to the Grey heron, a waterbird. Aquatic associated species have been documented to be important ESBL hosts as a result of human activities in their habitat [36,42]. Of note, ESBL strains were also detected in samples from a Eurasian Scops owl and a Common swift, two insectivorous birds that live in urbanized areas in vicinity to humans, possibly underlining the importance of human-derived environmental contamination in the dissemination of AMR. Nevertheless, a potential transmission via insects, such as houseflies, cannot be ruled out either [43,44]. Four of the birds that were found to be colonized by ESBL *E. coli* (Short-toed snake eagle, Steppe eagle, Grey heron, Common swift) are also migratory and could thus act as dispersion vectors across long distances [45].

Molecular characterization of the ESBL isolates revealed a dominance of *bla*CTX-M-1 group, which is consistent with the majority of published studies on wild avian species to date [12,32,46–51]. *E. coli* producing CTX-M group 1 β-lactamases, especially CTX-M-1 and CTX-M-15, has been described as an alarming cause of human infections globally, while variant CTX-M-1 further prevails among food-producing animals [52–54]. Notably, we also detected the acquired AmpC gene *bla*ACT in four of the isolates, but not *bla*CMY-2, even though prior studies worldwide as well as in Greece have described the latter as the most dominant plasmid encoded AmpC beta-lactamase gene in *Enterobacteriaceae* of wild bird origin [55–57]. Co-occurrence of *bla*ACT and *bla*CTX-M-1 group has previously been reported in an *Escherichia fergusonii* isolated from a Cattle egret in Tunisia [12].

Of special interest is the fact that a carbapenemase-producing, *bla*NDM positive *E. coli* was identified in the fecal sample of a Caspian gull. The species is one of the most numerous in Greece with a wide range of different feeding habitats. This particular bird was sampled in Porto Lagos, a coastal area in eastern Macedonia, within a wide wetland complex that includes a lagoon, lakes and numerous islands. This site is part of the Ramsar Convention and is regarded as a location of considerable ecological value for breeding and wintering waterbirds and raptors [58]. In Porto Lagos, Caspian gull individuals are either resident or may originate from several other regions, such as the Black Sea, having undertaken a lengthy migration, especially in their first calendar year [59]. Noteworthily, another NDM producing strain, namely a NDM-1 *Klebsiella pneumoniae* recovered from the feces of a Caspian gull, has recently been reported from the Azov-Black Sea in Ukraine [60]. Therefore, we could hypothesize that this resistance gene has been imported to Greece via migratory birds or alternatively that it circulates in the region due to human contamination. In most parts of the world, NDM-type MBLs are sporadically described among humans [3], however, studies in Greece during the past three years have outlined a wide dissemination and establishment of NDM-producing *Enterobacteriaceae* [61,62]. Given the fact that Caspian gulls frequently feed on anthropogenic food sources such as trawler discards and refuse dumps or nearby livestock-associated facilities such as slaughterhouses, uptake of the resistant strain or the resistance determinants during feeding could also be possible [63]. NDM-producing *E. coli* has also been recovered from other gull species and, in particular, from Yellow-legged gulls (*Larus michahellis*) in Spain, Lesser black-backed gulls (*Larus fuscus*) in Spain and Franklin’s gulls (*Larus pipixcan*) in Chile [60]. Additionally, Black kites (*Milvus migrans*) have been found to harbor *bla*NDM-5 *E. coli* in Pakistan and *bla*NDM-1 *Salmonella enterica* subsp. *enterica* serovar Corvallis in Germany, the latter being the first ever description of a carbapenemase producer isolated from wild animals [60,64]. Here we report, for the first time in Greece, the detection of a carbapenemase-producing organism from a wild bird, which was identified as NDM positive *E. coli*. 
Although our study focused on β-lactamase mediated resistance (ESBLs and carbapenemases), we additionally identified high rates of non-wild-type susceptibility to almost all the antibiotic classes tested, including tetracyclines, sulfonamides, trimethoprim and quinolones. Microarray analysis confirmed the presence of resistance genes against several antibiotics, with variants sul2, dfrA5, qnrS, mrx and aadA2 being the most frequently detected resistance determinants for sulfonamides, trimethoprim, quinolones, macrolides and aminoglycosides, respectively. The detection of multiple AMR genes in all the isolates probably indicates the wide dissemination of AMR determinants in the environment and could be attributed to the presence and cohabitation of transferable plasmids [17,65]. Moreover, two ESBL- and the carbapenemase-producing isolates carried intI1, a gene encoding an element known to play a crucial role in the recruitment, spread and expression of resistance genes [66]. Numerous earlier studies have shown an association of both blaCTX-M and blaNDM with the variable region of class 1 integrons in E. coli isolates of human and animal origin [67–70]. Among wild animals, intI1 presence is related to their close contact with humans, farm animals and pets [71]. However, previous research has presented a higher incidence of intI1 among ESBL producers isolated from wildlife varying between 72.4% and 100% [46,50,72], a discrepancy that requires further investigation.

5. Conclusions

This study provides evidence of wild birds’ colonization with ESBL- and carbapenemase-producing E. coli in Greece. The circulation of blaCTX-M-1 group, blaTEM and blaNDM, along with genes conferring resistance to five classes of non β-lactam antimicrobials (fluoroquinolones, trimethoprim, sulfonamides, aminoglycosides, macrolides), poses a serious threat for the spread of MDR bacteria. Thus, wild birds should be regarded as a reservoir, vehicle and indicator of AMR in the environment. Considering that ESBL-PE and CPE detection rates among humans in Greece remain high, regular surveillance studies are required to fully unveil the extent of wild birds’ role in the circulation of such pathogens.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/microorganisms10061217/s1, Supplementary File S1: Genes detected by the CarbaResist DNA microarray-based assay. Supplementary File S2: CarbaResist microarray layout.

Author Contributions: Conceptualization, Z.A., S.D.B., M.S., S.M., D.C.C., V.S., E.P., R.E. and C.B.; methodology, Z.A., S.D.B., M.S., D.G., D.K., V.S., E.P., R.E. and C.B.; software, C.D., S.D.B., D.G. and D.K.; validation, Z.A., S.D.B., M.S., S.M., A.T., P.B., R.E. and C.B.; formal analysis, Z.A., C.D., S.D.B., S.M. and R.E.; investigation, Z.A., C.D., S.D.B., D.C.C. and A.T.; resources, A.G., D.G., D.K., P.B., M.P. and G.G.; data curation, Z.A. and S.D.B.; writing—original draft preparation, Z.A.; writing—review and editing, Z.A., S.D.B., M.S., A.G., S.M., P.B., V.S., E.P., R.E. and C.B.; visualization, C.D. and S.D.B.; supervision, M.S., S.M., V.S., E.P., R.E. and C.B.; project administration, M.S., S.M., V.S., E.P., R.E. and C.B.; funding acquisition, S.D.B., M.S., A.G., S.M., D.C.C., V.S., E.P., R.E. and C.B. All authors have read and agreed to the published version of the manuscript.

Funding: This work was carried out under the project “Novel technologies for surveillance and characterization of Extended-spectrum β-lactamase and Carbapenemase producing Enterobacteriaceae, in humans and animals (CARBATECH)”, of the Bilateral S&T Cooperation Program Greece–Germany 2017. The European Union and the General Secretariat for Research and Innovation, Ministry of Development & Investments co-funded the Greek side (T2DGE-0944). The Federal Ministry of Education and Research funded the German side (01E11701 and 13GW0458D). This support is gratefully acknowledged.

Institutional Review Board Statement: Samples were obtained by noninvasive cloacal swabs and no research on animals, as defined in the EU Ethics for Researchers document (European Commission, 2013, Ethics for Researchers—Facilitating Research Excellence in FP7, Luxembourg: Office for Official Publications of the European Communities, ISBN 978-92-79-28854-8), was carried out for this study. Official permission for capturing and sampling migratory and resident wild birds was provided by the Hellenic Ministry of Environment and Energy (181997/1000/10-5-2019). Capturing, handling and sampling wild birds complied with European and national legislation and the study protocol
was approved by the academic board of the Veterinary Faculty of the University of Thessaly, Meeting 51/18.11.19.

**Data Availability Statement:** All data generated for this study are presented within the manuscript and the supplementary files.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. EClinicalMedicine. Antimicrobial Resistance: A Top Ten Global Public Health Threat. *EClinicalMedicine* 2021, 41, 101221. [CrossRef][PubMed]

2. Majiduddin, F.K.; Materon, I.C.; Palzkill, T.G. Molecular Analysis of Beta-Lactamase Structure and Function. *Int. J. Med. Microbiol.* 2002, 292, 127–137. [CrossRef][PubMed]

3. Logan, L.K.; Weinstein, R.A. The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace. *J. Infect. Dis.* 2017, 215, S28–S36. [CrossRef][PubMed]

4. Ang, H.; Sun, X. Risk Factors for Multidrug-Resistant Gram-Negative Bacteria Infection in Intensive Care Units: A Meta-Analysis. *Int. J. Nurs. Pract.* 2018, 24, e12644. [CrossRef][PubMed]

5. Ouchar Mahamat, O.; Kempf, M.; Lounnas, M.; Tidjani, A.; Hide, M.; Benavides, J.A.; Carrière, C.; Bañuls, A.-L.; Jean-Pierre, H.; Ouedraogo, A.-S.; et al. Epidemiology and Prevalence of Extended-Spectrum β-Lactamase- and Carbapenemase-Producing Enterobacteriaceae in Humans, Animals and the Environment in West and Central Africa. *Int. J. Antimicrob. Agents* 2021, 57, 106203. [CrossRef]

6. Köck, R.; Herr, C.; Kreienbrock, L.; Schwarz, S.; Tenhagen, B.-A.; Walther, B. Multiresistant Gram-Negative Pathogens. *Dttsch. Ärzteblatt Int.* 2021, 118, 579–586. [CrossRef]

7. Carattoli, A. Importance of Integrons in the Diffusion of Resistance. *Vet. Res.* 2001, 32, 243–259. [CrossRef]

8. Fernández-Garcia, L.; Blasco, L.; Lopez, M.; Bou, G.; García-Contreras, R.; Wood, T.; Tomas, M. Toxin-Antitoxin Systems in Clinical Pathogens. *Toxins* 2016, 8, 227. [CrossRef]

9. Torres, R.T.; Carvalho, J.; Cunha, M.V.; Serrano, E.; Palmeira, J.D.; Fonseca, C. Temporal and Geographical Research Trends of Antimicrobial Resistance in Wildlife—A Bibliometric Analysis. *One Health* 2020, 11, 100198. [CrossRef]

10. Wang, J.; Ma, Z.B.; Zeng, Z.L.; Yang, X.W.; Huang, Y.; Liu, J.H. The Role of Wildlife (Wild Birds) in the Global Transmission of Antimicrobial Resistance Genes. *Zool. Res.* 2017, 38, 55–80. [CrossRef]

11. Skarżyńska, M.; Zając, M.; Bomba, A.; Bocian, Ł.; Kozdruń, W.; Polak, M.; Wiacek, J.; Wasyl, D. Antimicrobial Resistance Glides in the Sky—Free-Living Birds as a Reservoir of Resistant Escherichia Coli with Zoonotic Potential. *Front. Microbiol.* 2021, 12, 656223. [CrossRef][PubMed]

12. Ben Yahia, H.; Chariat, S.; Gharsa, H.; Alonso, C.A.; Ben Sallem, R.; Porres-Osante, N.; Hamdi, N.; Torres, C.; Ben Slama, K. First Report of KPC-2 and KPC-3-Producing Enterobacteriaceae in Wild Birds in Africa. *Microb Ecol* 2020, 79, 30–37. [CrossRef][PubMed]

13. Cunha, M.P.V.; Oliveira, M.C.V.; Oliveira, M.G.X.; Menão, M.C.; Knöbl, T. CTX-M-Producing Escherichia Coli Isolated from Urban Pigeons (Columba Livia Domestica) in Brazil. *J. Infect. Dev. Ctries.* 2019, 13, 1052–1056. [CrossRef][PubMed]

14. Schaufler, K.; Semmler, T.; Wieler, L.H.; Wöhrmann, M.; Baddam, R.; Ahmed, N.; Müller, K.; Kola, A.; Fruth, A.; Ewers, C.; et al. Clonal Spread and Interspecies Transmission of Clinically Relevant ESBL-Producing Escherichia Coli of ST410—Another Successful Pandemic Clone? *FEMS Microbiol. Ecol.* 2016, 92, fiv155. [CrossRef][PubMed]

15. Poirel, L.; Madec, J.-Y.; Lupo, A.; Schink, A.-K.; Kieffer, N.; Nordmann, P.; Schwarz, S. Antimicrobial Resistance in Escherichia Coli. *Microbiol. Spectr.* 2018, 6, 64.14. [CrossRef][PubMed]

16. Van Duin, D.; Doi, Y. The Global Epidemiology of Carbapenemase-Producing Enterobacteriaceae. *Virulence* 2016, 8, 460–469. [CrossRef]

17. Bush, K.; Bradford, P.A. Epidemiology of β-Lactamase-Producing Pathogens. *Clin. Microbiol. Rev.* 2020, 33, e00047-19. [CrossRef]

18. Paitan, Y. Current Trends in Antimicrobial Resistance of Escherichia Coli. In *Escherichia coli, a Versatile Pathogen*; Frankel, G., Ron, E.Z., Eds.; Current Topics in Microbiology and Immunology; Springer International Publishing: Cham, Switzerland, 2018; pp. 181–211, ISBN 978-3-319-99664-6.

19. Miyakis, S.; Pefanis, A.; Tsakis, A. The Challenges of Antimicrobial Drug Resistance in Greece. *Clin. Infect. Dis.* 2011, 53, 177–184. [CrossRef]

20. Mavroidi, A.; Liakopoulou, A.; Gounaris, A.; Goudesidou, M.; Gaitana, K.; Miriagou, V.; Petinaki, E. Successful Control of a Neonatal Outbreak Caused Mainly by ST20 Multidrug-Resistant SHV-5-Producing Klebsiella Pneumoniae, Greece. *BMC Pediatrics* 2014, 14, 105. [CrossRef]

21. Lebessi, E.; Dillagermatticas, H.; Tassios, P.T.; Tzouvelekis, L.S.; Ioannidou, S.; Feustoukou, M.; Legakis, N.J. Extended-Spectrum β-Lactamase-Producing Klebsiella Pneumoniae in a Neonatal Intensive Care Unit in the High-Prevalence Area of Athens, Greece. *J. Clin. Microbiol.* 2002, 40, 799–804. [CrossRef]

22. Brolund, A.; Lagerqvist, N.; Byfors, S.; Struelens, M.J.; Monnet, D.L.; Albigere, B.; Kohlenberg, A. Worsening Epidemiological Situation of Carbapenemase-Producing Enterobacteriaceae in Europe, Assessment by National Experts from 37 Countries, July 2018. *Eurosurveillance* 2019, 24, 1900123. [CrossRef]
23. Karampatakis, T.; Antachopoulos, C.; Tsakris, A.; Rolilides, E. Molecular Epidemiology of Carbapenem-Resistant Pseudomonas Aeruginosa in an Endemic Area: Comparison with Global Data. *Eur. J. Clin. Microbiol. Infect. Dis.* 2018, 37, 1211–1220. [CrossRef] [PubMed]

24. Karampatakis, T.; Antachopoulos, C.; Tsakris, A.; Rolilides, E. Molecular Epidemiology of Carbapenem-Resistant Acinetobacter Baumannii in Greece: An Extended Review (2000–2015). *Future Microbiol.* 2017, 12, 801–815. [CrossRef] [PubMed]

25. Suay-García, B.; Pérez-Gracia, M.T. Present and Future of Carbapenem-Resistant Enterobacteriaceae (CRE) Infections. *Antibiotics* 2019, 8, 122. [CrossRef] [PubMed]

26. Giske, C.G.; Martínez-Martínez, L.; Cantón, R.; Stefani, S.; Skov, R.; Glupczynski, Y.; Nordmann, P.; Wootton, M.; Miraigou, V.; Skov Simonsen, G.; et al. **EUCART Guidelines for Detection of Resistance Mechanisms and Specific Resistances of Clinical and/or Epidemiological Importance; European Committee on Antimicrobial Susceptibility Testing; Växjö, Sweden, 2017.**

27. Braun, S.D.; Jamil, B.; Syed, M.A.; Abbasi, S.A.; Weiße, D.; Slickers, P.; Monecke, S.; Engelmann, I.; Ehrlich, R. Prevalence of Carbapenemase-Producing Organisms at the Kidney Center of Rawalpindi (Pakistan) and Evaluation of an Advanced Molecular Microarray-Based Carbapenemase Assay. *Future Microbiol.* 2018, 13, 1225–1246. [CrossRef]

28. Oteo, J.; Mencía, A.; Bautista, V.; Pastor, N.; Lara, N.; González-González, F.; García-Peña, F.J.; Campos, J. Colonization with Enterobacteriaceae-Producing ESBLs, AmpCs, and OXA-48 in Wild Avian Species, Spain 2015–2016. *Microb. Drug Resist.* 2018, 24, 932–938. [CrossRef]

29. Báez, J.; Hernández-García, M.; Guamparito, C.; Díaz, S.; Olave, A.; Guerrero, K.; Cantón, R.; Baquero, F.; Gahona, J.; Valenzuela, N.; et al. Molecular Characterization and Genetic Diversity of ESBL-Producing Escherichia coli Colonizing the Migratory Franklin’s Gulls (Leucophaeus pipixcan) in Antofagasta, North of Chile. *Microb. Drug Resist.* 2015, 21, 111–116. [CrossRef] [PubMed]

30. Vergara, A.; Pitart, C.; Montalvo, T.; Roca, I.; Sabaté, S.; Hurtado, J.C.; Planell, R.; Marco, F.; Ramírez, B.; Perachó, V.; et al. Prevalence of Extended-Spectrum β-Lactamase- and/or Carbapenemase-Producing Escherichia coli Isolated from Yellow-Legged Gulls from Barcelona, Spain. *Antimicrob. Agents Chemother.* 2017, 61, e02071-16. [CrossRef] [PubMed]

31. Mohsin, M.; Raza, S.; Schaufler, K.; Roschanski, N.; Sarwar, F.; Semmler, T.; Schierack, P.; Guenther, S. High Prevalence of CTX-M-15-Type ESBL-Producing E. coli from Migratory Avian Species in Pakistan. *Front. Microbiol.* 2017, 8, 2476. [CrossRef] [PubMed]

32. Veldman, K.; van Tullen, P.; Kant, A.; Testerink, J.; Mevius, D. Characteristics of Cefotaxime-Resistant Escherichia coli from Wild Birds in The Netherlands. *Appl. Environ. Microbiol.* 2013, 79, 7556–7561. [CrossRef]

33. Bouaziz, A.; Loucif, L.; Ayachi, A.; Guehaz, K.; Bendjama, E.; Rolain, J.-M. Migratory White Stork (Ciconia ciconia): A Potential Vector of the O25b-ST131 Clone Harboring BlaCTX-M-8. *Front. Microbiol.* 2018, 9, 371. [CrossRef] [PubMed]

34. Zeballos-Gross, D.; Rojas-Sereno, Z.; Salgado-Caxito, M.; Poeta, P.; Torres, C.; Benavides, J.A. The Role of Gulls as Reservoirs of Antibiotic Resistance in Aquatic Environments: A Scoping Review. *Front. Microbiol.* 2021, 12, 1938. [CrossRef]

35. Dolejska, M.; Masarikova, M.; Dobiasova, H.; Jamborova, I.; Karpiskova, R.; Havlicek, M.; Carlile, N.; Priddel, D.; Cizek, A.; Literak, I. High Prevalence of Salmonella and IMP-4-Producing Enterobacteriaceae. *Int. J. Infect. Dis.* 2014, 18, 59–65. [CrossRef]

36. Chung, D.M.; Ferree, E.; Simon, D.M.; Yeh, P.J. Patterns of Bird-Bacteria Associations. *EcoHealth* 2018, 15, 627. [CrossRef]

37. Miller, E.A.; Ponder, J.B.; Willette, M.; Johnson, T.J.; VanderWaal, K.L. Merging Metagenomics and Spatial Epidemiology to Understand the Distribution of Antimicrobial Resistance Genes from Enterobacteriaceae in Wild Owls. *Appl. Environ. Microbiol.* 2020, 86, 20. [CrossRef]

38. Zevallos-Gross, D.; Rojas-Sereno, Z.; Salgado-Caxito, M.; Poeta, P.; Torres, C.; Benavides, J.A. The Role of Gulls as Reservoirs of Antibiotic Resistance in Aquatic Environments: A Scoping Review. *Front. Microbiol.* 2021, 12, 1938. [CrossRef]

39. Solá-Gineis, M.; González-López, J.J.; Cameron-Veas, K.; Piedra-Carrasco, N.; Cerdá-Cuellar, M.; Migura-García, L. Houseflies (Musca Domestica) as Vectors for Extended-Spectrum β-Lactamase-Producing Escherichia coli on Spanish Broiler Farms. *Appl. Environ. Microbiol.* 2015, 81, 3604–3611. [CrossRef] [PubMed]
44. Poudel, A.; Hathcock, T.; Butaye, P.; Kang, Y.; Price, S.; Macklin, K.; Walz, P.; Cattley, R.; Kalalah, A.; Adekanambi, F.; et al. Multidrug-Resistant Escherichia Coli, Klebsiella Pneumoniae and Staphylococcus Spp. in Housefowls and Blowflies from Farms and Their Environmental Settings. *Int. J. Environ. Res. Public Health* **2019**, *16*, 3583. [CrossRef] [PubMed]

45. Sandgren, L.; Steedt, J.; Lustig, U.; Bonnedahl, J.; Andersson, D.I.; Järhult, J.D. Long-Term Carriage and Rapid Transmission of Extended Spectrum Beta-Lactamase-Producing E. Coli within a Flock of Mallards in the Absence of Antibiotic Selection: Carriage and Transmission of ESBL in Mallards. *Environ. Microbiol. Rep.* **2018**, *10*, 576–582. [CrossRef] [PubMed]

46. Fasahae, K.; Engellmann, I.; Monecke, S.; Braun, S.D.; Ehrlich, R. Molecular Characterisation of Extended-Spectrum β-Lactamase Producing Escherichia Coli in Wild Birds and Cattle, Idaho, Nigeria. *BMC Vet. Res.* **2021**, *17*, 33. [CrossRef] [PubMed]

47. Blanco, G.; López-Hernández, I.; Morinha, F.; López-Cerero, L. Intensive Farming as a Source of Bacterial Resistance to Antimicrobial Agents in Sedentary and Migratory Vultures: Implications for Local and Transboundary Spread. *Sci. Total Environ.* **2020**, *739*, 140356. [CrossRef]

48. Zurfluh, K.; Albini, S.; Mattmann, P.; Kindle, P.; Nüesch-Inderbinen, M.; Stephan, R.; Vogler, B.R. Antimicrobial Resistant and Extended-spectrum β-Lactamase Producing Escherichia Coli in Common Wild Bird Species in Switzerland. *MicrobiologyOpen* **2019**, *8*, e845. [CrossRef]

49. Ngaiganam, E.P.; Pagnier, I.; Chaalal, W.; Leangapichart, T.; Chabou, S.; Rolain, J.-M.; Diene, S.M. Investigation of Urban Birds as Source of β-Lactamase-Producing Gram-Negative Bacteria in Marseille City, France. *Acta Vet. Scand.* **2019**, *61*, 51. [CrossRef]

50. Ben Yahia, H.; Ben Sallem, R.; Tayh, G.; Klibi, N.; Ben Amor, I.; Gharsa, H.; Boudabbous, A.; Ben Slama, K. Detection of CTX-M-15 Harboring Escherichia Coli isolated from Wild Birds and Cattle, Tunisia. *BMC Microbiol.* **2018**, *18*, 26. [CrossRef]

51. Raza, S.; Mohsin, M.; Madni, W.A.; Sarwar, F.; Saqib, M.; Aslam, B. First Report of Bla CTX-M-15-Type ESBL-Producing Klebsiella Pneumoniae Serovar Corvallis Isolated from a Wild Bird in Germany. *J. Ornithol.* **2018–2021**, 2197–2202. [CrossRef]

52. Naseer, S.; Mohsin, M.; Madni, W.A.; Haldorsen, B.C.; Bue, B.; Grundt, H.; Walsh, T.R.; Sundsfjord, A. Nosocomial Outbreak of CTX-M-15-Producing E. Coli in Norway. *Acta Pathol. Microbiol. Immunol. Scand.* **2008**, *153*, 223. [CrossRef] [PubMed]

53. Athanasakopoulou, Z.; Tsilipounidaki, K.; Sofia, M.; Chatzopoulos, D.C.; Giannakopoulos, A.; Karakousis, I.; Giannakis, V.; Spyrou, V.; Touloudi, A.; Satra, M.; et al. Poultry and Wild Birds as a Reservoir of CMY-2 Producing Escherichia Coli: The First Large-Scale Study in Greece. *Antibiotics* **2021**, *10*, 235. [CrossRef] [PubMed]

54. Chong, Y.; Shimoda, S.; Shimono, N. Current Epidemiology, Genetic Evolution and Clinical Impact of Extended-Spectrum β-Lactamase-Producing Escherichia Coli and Klebsiella Pneumoniae. *Infect. Genet. Evol.* **2018**, *61*, 185–188. [CrossRef] [PubMed]

55. Jamborova, I.; Dolejska, M.; Vojtech, J.; Guenther, S.; Uricariu, R.; Drozdowska, J.; Papousek, I.; Meissner, W.; Nüesch-Inderbinen, M.; Stephan, R.; Vogler, B.R.; et al. Plasma-Mediated Resistance to Cephalosporins and Fluoroquinolones in Various Escherichia Coli Sequence Types Isolated from Rooks Wintering in Europe. *Appl. Environ. Microbiol.* **2015**, *81*, 648–657. [CrossRef]

56. Potrel, L.; Potron, A.; De La Cuesta, C.; Cleary, T.; Nordmann, P.; Munoz-Price, L.S. Wild Coastline Birds as Reservoirs of Broad-Spectrum β-Lactamase-Producing Enterobacteriaceae in Miami Beach, Florida. *Antimicrob. Agents Chemother.* **2012**, *56*, 2756–2758. [CrossRef]

57. Politi, L.; Gartzonika, K.; Spanakis, N.; Zarkotou, O.; Poulou, A.; Skoura, L.; Vrioni, G.; Tsakris, A. Emergence of NDM-1-Producing Klebsiella Pneumoniae as Commensal and Pathogenic Bacteria among Food-Producing Animals: Health Implications of Extended Spectrum β-Lactamase (ESBL) Production. *Animals* **2020**, *10*, 2239. [CrossRef] [PubMed]

58. Řeřáková, P.; Bártová, D.; Benešová, V.; Œíbal, P.; Hlavatík, S.; Havlíková, L. Intensive Farming as a Source of Bacterial Resistance to Antimicro-
67. Shams, F.; Hasani, A.; Ahangarzadeh Rezaee, M.; Nahaie, M.R.; Hasani, A.; Soroush Bar Haghi, M.H.; Pormohammad, A.; Elli Arbatan, A. Carriage of Class 1 and 2 Integrons in Quinolone, Extended-Spectrum-β-Lactamase-Producing and Multi Drug Resistant E.Coli and K.Pneumoniae: High Burden of Antibiotic Resistance. *Adv. Pharm. Bull.* **2015**, *5*, 335–342. [CrossRef] [PubMed]

68. Taghadosi, R.; Shakibaie, M.R.; Hosseini-Nave, H. Antibiotic Resistance, ESBL Genes, Integrons, Phylogenetic Groups and MLVA Profiles of Escherichia Coli Pathotypes Isolated from Patients with Diarrhea and Farm Animals in South-East of Iran. *Comp. Immunol. Microbiol. Infect. Dis.* **2019**, *63*, 117–126. [CrossRef] [PubMed]

69. Novais, Â.; Cantón, R.; Valverde, A.; Galán, J.-C.; Peixe, L.; Carattoli, A.; Baquero, F.; Coque, T.M. Dissemination and Persistence of BlaCTX-M-9 Are Linked to Class 1 Integrons Containing CR1 Associated with Defective Transposon Derivatives from Tn402 Located in Early Antibiotic Resistance Plasmids of IncHI2, IncP1-α, and IncFI Groups. *Antimicrob. Agents Chemother.* **2006**, *50*, 2741–2750. [CrossRef] [PubMed]

70. Le-Vo, H.-N.; Tran, P.T.-B.; Le, L.; Matsumoto, Y.; Motooka, D.; Nakamura, S.; Jones, J.W.; Iida, T.; Cao, V. Complex Class 1 Integron in a Clinical Escherichia Coli Strain from Vietnam Carrying Both Mcr-1 and BlaNDM-1. *Front. Microbiol.* **2019**, *10*, 2472. [CrossRef]

71. Dolejska, M.; Cizek, A.; Literak, I. High Prevalence of Antimicrobial-Resistant Genes and Integrons in Escherichia Coli Isolates from Black-Headed Gulls in the Czech Republic. *J. Appl. Microbiol.* **2007**, *103*, 11–19. [CrossRef]

72. Rybak, B.; Krawczyk, B.; Furmanek-Blaszk, B.; Wysocka, M.; Fordon, M.; Ziolkowski, P.; Meissner, W.; Stepniewska, K.; Sikorska, K. Antibiotic Resistance, Virulence, and Phylogenetic Analysis of Escherichia Coli Strains Isolated from Free-Living Birds in Human Habitats. *PLoS ONE* **2022**, *17*, e0262236. [CrossRef]